AMSBIO announces an extensive range of primary human cancer cells obtained directly from a variety tumour types, including breast, colon and prostate.
Despite significant advances in cancer research and treatments, the eradication of the disease remains elusive. This has led to a more urgent focus on precision medicine and advanced treatments like immunotherapy and the use of oncolytic viruses. Donor derived primary tumour cells offer a more in vivo like model potentially enhancing the development of targeted personalised therapeutics.
It is known that using immortalised cell lines as surrogates poorly reflects the diverse profiles tumours have. During long-term culture immortalised cells adapt to their in vitro environment, and often mask or lose the in vivo phenotypic events being studied in addition to hiding key epigenetic or immunotherapy markers. These shortfalls highlight a need for new in vitro cancer models that utilise primary tumour cells that more closely reproduce the in vivo cancer microenvironment.
Provided with the original pathological diagnoses and analysed for key mutations, AMSBIO primary human cancer cells present the real characteristics of their in vivo state, remain heterogeneous for several passages and thus enhance pharmacogenetic and molecular diagnostic testing abilities. These patient specific cells add to a range of products offered by AMSBIO to help researchers develop more physiologically relevant models to study cell behaviour.
